CancerDrs

Leukemia clinical trials in Georgia

40 actively recruiting leukemia trials at 5 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
  • Augusta University Medical Center — Augusta, Georgia
  • Memorial Health University Medical Center — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…

Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Georgia:
  • University of Emory - Winship Cancer Institute — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into…

Sponsor: Moleculin Biotech, Inc.
NCT ID: NCT06788756
Sites in Georgia:
  • Augusta University - Georgia Cancer Center — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Georgia:
  • Phoebe Putney Memorial Hospital — Albany, Georgia
  • Augusta University Medical Center — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Georgia:
  • Phoebe Putney Memorial Hospital — Albany, Georgia
  • Augusta University Medical Center — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Georgia:
  • Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
  • Memorial Health University Medical Center — Savannah, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Georgia:
  • Phoebe Putney Memorial Hospital — Albany, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Georgia:
  • Augusta University — Augusta, Georgia
  • Southeastern Regional Medical Center — Newnan, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…

Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Georgia:
  • Children's Healthcare of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…

Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Georgia:
  • Children's Healthcare of Atlanta at Egleston — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …

Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Georgia:
  • Children's Hospital of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-lin…

Sponsor: AbbVie
NCT ID: NCT04895436
Sites in Georgia:
  • Winship Cancer Institute of Emory University /ID# 230643 — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blas…

Sponsor: Aptose Biosciences Inc.
NCT ID: NCT03850574
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood…

Sponsor: Fred Hutchinson Cancer Center
NCT ID: NCT03779854
Sites in Georgia:
  • Children's Healthcare of Atlanta — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

Sponsor: Massachusetts General Hospital
NCT ID: NCT06707493
Sites in Georgia:
  • Emory University Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Trans…

Sponsor: Christine Ryan
NCT ID: NCT06043674
Sites in Georgia:
  • Winship Cancer Institute at Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytok…

Sponsor: Northside Hospital, Inc.
NCT ID: NCT05519579
Sites in Georgia:
  • Northside Hospital — Atlanta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Georgia:
  • Emory Healthcare - The Emory Clinic — Atlanta, Georgia
  • Georgia Cancer Center at Augusta University — Augusta, Georgia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Georgia:
  • Emory University — Atlanta, Georgia
View on ClinicalTrials.gov →

Showing 25 of 40 trials with sites in Georgia. See all leukemia trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10